

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

Claims 1-27 (cancelled).

¹ ~~28~~. (presently amended): A method of making an antibody that specifically binds to phosphatidylserine, said method comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylserine/polypeptide conjugate composition, wherein the phosphatidylserine is covalently coupled to the polypeptide.

² ~~29~~. (previously presented): The method of claim ¹~~28~~, wherein a composition comprising phosphatidylserine/BSA, phosphatidylserine/KLH, phosphatidylserine/BGG, or phosphatidylserine/ β_2 -glycoprotein I conjugate is administered to the animal.

Amended
5/25/04

Claims 30-36 (cancelled).

³ ~~37~~. (previously presented): The method of claim ²~~29~~, wherein said polypeptide is β_2 -glycoprotein I.

⁴ ~~38~~. (previously presented): The method of claim ¹~~28~~, wherein the antibody is linked to a detectable label.

⁵ ~~39~~. (previously presented): The method of claim ⁴~~38~~, wherein the antibody is linked to a radioactive label, a fluorogenic-label, a nuclear magnetic spin resonance label, biotin or an enzyme that generates a detectable product upon contact with a chromogenic substrate.

⁶ ~~40~~. (previously presented): The method of claim ⁴~~38~~, wherein the antibody is linked to an alkaline phosphatase, hydrogen peroxidase or glucose oxidase enzyme.

7
41. (previously presented): The method of claim ¹28, wherein the antibody is a monoclonal antibody.

8
42. (presently amended): A method of making an antibody that specifically binds to phosphatidylserine, said method comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylserine/polypeptide conjugate composition, wherein the phosphatidylserine/polypeptide conjugate composition is not a phosphatidylserine/KLH conjugate composition, and wherein the phosphatidylserine is covalently coupled to the polypeptide.

9
43. (previously presented): The method of claim ⁸42, wherein the pharmaceutical composition comprises a phosphatidylserine/BSA, phosphatidylserine/BGG, or phosphatidylserine/ β_2 -glycoprotein I conjugate.

10
44. (previously presented): The method of claim ⁹43, wherein said polypeptide is β_2 -glycoprotein I.

11
45. (previously presented): The method of claim ⁸42, wherein the antibody is linked to a detectable label.

12
46. (previously presented): The method of claim ¹¹45, wherein the antibody is linked to a radioactive label, a fluorogenic label, a nuclear magnetic spin resonance label, biotin or an enzyme that generates a detectable product upon contact with a chromogenic substrate.

13
47. (previously presented): The method of claim ¹¹45, wherein the antibody is linked to an alkaline phosphatase, hydrogen peroxidase or glucose oxidase enzyme.

14
48. (previously presented): The method of claim ⁸42, wherein the antibody is a monoclonal antibody.

¹⁵
~~49~~. (presently amended): A method of making a monoclonal antibody that specifically binds to phosphatidylserine, said method comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylserine/polypeptide conjugate composition, wherein the phosphatidylserine is covalently coupled to the polypeptide.

¹⁶
~~50~~. (previously presented): The method of claim ¹⁵~~49~~, wherein the pharmaceutical composition comprises a phosphatidylserine/BSA, phosphatidylserine/BGG, or phosphatidylserine/ β_2 -glycoprotein I conjugate.

¹⁷
~~51~~. (previously presented): The method of claim ¹⁶~~50~~, wherein said polypeptide is β_2 -glycoprotein I.

¹⁸
~~52~~. (previously presented): The method of claim ¹⁵~~49~~, wherein the antibody is linked to a detectable label.

¹⁹
~~53~~. (previously presented): The method of claim ¹⁸~~52~~, wherein the antibody is linked to a radioactive label, a fluorogenic label, a nuclear magnetic spin resonance label, biotin or an enzyme that generates a detectable product upon contact with a chromogenic substrate.

²⁰
~~54~~. (previously presented): The method of claim ¹⁸~~53~~, wherein the antibody is linked to an alkaline phosphatase, hydrogen peroxidase or glucose oxidase enzyme.